Organovo presents near-term value catalysts for FXR314 at Jones Trading Conference. Strong preclinical and human case for FXR314 in ulcerative colitis P2 2
Organovo Holdings (Nasdaq: ONVO) presented its prospects and plans at the Jones Trading Healthcare Conference, focusing on FXR314its treatment for...
